Diagnostic performance of EUS in predicting advanced cancer among patients with Barrett's esophagus and high-grade dysplasia/early adenocarcinoma

Systematic review and meta-analysis

Bashar J. Qumseya, Jessica Brown, Merna Abraham, Donna White, Herbert Wolfsen, Neil Gupta, Prashanth Vennalaganti, Prateek Sharma, Michael B. Wallace

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background The role of EUS among patients with Barrett's esophagus (BE) with high-grade dysplasia (HGD) or suspected mucosal carcinoma is controversial. Objective To define the role of EUS in detecting advanced disease among patients with BE. Design Systematic review and meta-analysis. Setting MEDLINE, Embase, Web of Science, and Cochrane Central databases. Patients Patients with BE and HGD or esophageal adenocarcinoma (EAC) who were referred for endoscopic evaluation and underwent EUS. Interventions EUS. Main Outcome Measurements Pooled proportion of patients with advanced EAC identified by EUS among patients with BE who are referred for HGD or EAC (with or without visible lesions). Forest plots were used to contrast effect sizes in each of the studies and random effect models when tests of heterogeneity were significant (I2 > 50% or P <.1 for the Q statistic). Results Of 1278 articles, 47 were reviewed in full text, and 11 articles met the inclusion criteria, including a total of 656 patients. Based on a random-effects model, the proportion of patients with advanced disease detected on EUS was 14% (95% confidence interval, 8%-22%; P <.0001). In a subanalysis, the pooled proportion of patients with advanced disease on EUS in the absence of nodules was 4% (95% confidence interval, 2%-6%, P <.0001). Limitations Significant heterogeneity among studies. Conclusions EUS will result in a change in the therapeutic approach among in a significant minority of patients with BE who are referred for HGD or EAC.

Original languageEnglish (US)
Pages (from-to)865-874
Number of pages10
JournalGastrointestinal Endoscopy
Volume81
Issue number4
DOIs
StatePublished - Apr 1 2015

Fingerprint

Barrett Esophagus
Meta-Analysis
Adenocarcinoma
Neoplasms
Confidence Intervals
MEDLINE
Databases
Carcinoma

ASJC Scopus subject areas

  • Gastroenterology
  • Radiology Nuclear Medicine and imaging

Cite this

Diagnostic performance of EUS in predicting advanced cancer among patients with Barrett's esophagus and high-grade dysplasia/early adenocarcinoma : Systematic review and meta-analysis. / Qumseya, Bashar J.; Brown, Jessica; Abraham, Merna; White, Donna; Wolfsen, Herbert; Gupta, Neil; Vennalaganti, Prashanth; Sharma, Prateek; Wallace, Michael B.

In: Gastrointestinal Endoscopy, Vol. 81, No. 4, 01.04.2015, p. 865-874.

Research output: Contribution to journalArticle

Qumseya, Bashar J. ; Brown, Jessica ; Abraham, Merna ; White, Donna ; Wolfsen, Herbert ; Gupta, Neil ; Vennalaganti, Prashanth ; Sharma, Prateek ; Wallace, Michael B. / Diagnostic performance of EUS in predicting advanced cancer among patients with Barrett's esophagus and high-grade dysplasia/early adenocarcinoma : Systematic review and meta-analysis. In: Gastrointestinal Endoscopy. 2015 ; Vol. 81, No. 4. pp. 865-874.
@article{4e51c255f3c14d76a587ba2f0eb1df4f,
title = "Diagnostic performance of EUS in predicting advanced cancer among patients with Barrett's esophagus and high-grade dysplasia/early adenocarcinoma: Systematic review and meta-analysis",
abstract = "Background The role of EUS among patients with Barrett's esophagus (BE) with high-grade dysplasia (HGD) or suspected mucosal carcinoma is controversial. Objective To define the role of EUS in detecting advanced disease among patients with BE. Design Systematic review and meta-analysis. Setting MEDLINE, Embase, Web of Science, and Cochrane Central databases. Patients Patients with BE and HGD or esophageal adenocarcinoma (EAC) who were referred for endoscopic evaluation and underwent EUS. Interventions EUS. Main Outcome Measurements Pooled proportion of patients with advanced EAC identified by EUS among patients with BE who are referred for HGD or EAC (with or without visible lesions). Forest plots were used to contrast effect sizes in each of the studies and random effect models when tests of heterogeneity were significant (I2 > 50{\%} or P <.1 for the Q statistic). Results Of 1278 articles, 47 were reviewed in full text, and 11 articles met the inclusion criteria, including a total of 656 patients. Based on a random-effects model, the proportion of patients with advanced disease detected on EUS was 14{\%} (95{\%} confidence interval, 8{\%}-22{\%}; P <.0001). In a subanalysis, the pooled proportion of patients with advanced disease on EUS in the absence of nodules was 4{\%} (95{\%} confidence interval, 2{\%}-6{\%}, P <.0001). Limitations Significant heterogeneity among studies. Conclusions EUS will result in a change in the therapeutic approach among in a significant minority of patients with BE who are referred for HGD or EAC.",
author = "Qumseya, {Bashar J.} and Jessica Brown and Merna Abraham and Donna White and Herbert Wolfsen and Neil Gupta and Prashanth Vennalaganti and Prateek Sharma and Wallace, {Michael B.}",
year = "2015",
month = "4",
day = "1",
doi = "10.1016/j.gie.2014.08.025",
language = "English (US)",
volume = "81",
pages = "865--874",
journal = "Gastrointestinal Endoscopy",
issn = "0016-5107",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - Diagnostic performance of EUS in predicting advanced cancer among patients with Barrett's esophagus and high-grade dysplasia/early adenocarcinoma

T2 - Systematic review and meta-analysis

AU - Qumseya, Bashar J.

AU - Brown, Jessica

AU - Abraham, Merna

AU - White, Donna

AU - Wolfsen, Herbert

AU - Gupta, Neil

AU - Vennalaganti, Prashanth

AU - Sharma, Prateek

AU - Wallace, Michael B.

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Background The role of EUS among patients with Barrett's esophagus (BE) with high-grade dysplasia (HGD) or suspected mucosal carcinoma is controversial. Objective To define the role of EUS in detecting advanced disease among patients with BE. Design Systematic review and meta-analysis. Setting MEDLINE, Embase, Web of Science, and Cochrane Central databases. Patients Patients with BE and HGD or esophageal adenocarcinoma (EAC) who were referred for endoscopic evaluation and underwent EUS. Interventions EUS. Main Outcome Measurements Pooled proportion of patients with advanced EAC identified by EUS among patients with BE who are referred for HGD or EAC (with or without visible lesions). Forest plots were used to contrast effect sizes in each of the studies and random effect models when tests of heterogeneity were significant (I2 > 50% or P <.1 for the Q statistic). Results Of 1278 articles, 47 were reviewed in full text, and 11 articles met the inclusion criteria, including a total of 656 patients. Based on a random-effects model, the proportion of patients with advanced disease detected on EUS was 14% (95% confidence interval, 8%-22%; P <.0001). In a subanalysis, the pooled proportion of patients with advanced disease on EUS in the absence of nodules was 4% (95% confidence interval, 2%-6%, P <.0001). Limitations Significant heterogeneity among studies. Conclusions EUS will result in a change in the therapeutic approach among in a significant minority of patients with BE who are referred for HGD or EAC.

AB - Background The role of EUS among patients with Barrett's esophagus (BE) with high-grade dysplasia (HGD) or suspected mucosal carcinoma is controversial. Objective To define the role of EUS in detecting advanced disease among patients with BE. Design Systematic review and meta-analysis. Setting MEDLINE, Embase, Web of Science, and Cochrane Central databases. Patients Patients with BE and HGD or esophageal adenocarcinoma (EAC) who were referred for endoscopic evaluation and underwent EUS. Interventions EUS. Main Outcome Measurements Pooled proportion of patients with advanced EAC identified by EUS among patients with BE who are referred for HGD or EAC (with or without visible lesions). Forest plots were used to contrast effect sizes in each of the studies and random effect models when tests of heterogeneity were significant (I2 > 50% or P <.1 for the Q statistic). Results Of 1278 articles, 47 were reviewed in full text, and 11 articles met the inclusion criteria, including a total of 656 patients. Based on a random-effects model, the proportion of patients with advanced disease detected on EUS was 14% (95% confidence interval, 8%-22%; P <.0001). In a subanalysis, the pooled proportion of patients with advanced disease on EUS in the absence of nodules was 4% (95% confidence interval, 2%-6%, P <.0001). Limitations Significant heterogeneity among studies. Conclusions EUS will result in a change in the therapeutic approach among in a significant minority of patients with BE who are referred for HGD or EAC.

UR - http://www.scopus.com/inward/record.url?scp=84925347502&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925347502&partnerID=8YFLogxK

U2 - 10.1016/j.gie.2014.08.025

DO - 10.1016/j.gie.2014.08.025

M3 - Article

VL - 81

SP - 865

EP - 874

JO - Gastrointestinal Endoscopy

JF - Gastrointestinal Endoscopy

SN - 0016-5107

IS - 4

ER -